Sulfamethoxazole drug stress upregulates antioxidant immunomodulatory metabolites in Escherichia coli.


Journal

Nature microbiology
ISSN: 2058-5276
Titre abrégé: Nat Microbiol
Pays: England
ID NLM: 101674869

Informations de publication

Date de publication:
11 2020
Historique:
received: 30 09 2019
accepted: 29 06 2020
pubmed: 29 7 2020
medline: 3 2 2021
entrez: 29 7 2020
Statut: ppublish

Résumé

Escherichia coli is an important model organism in microbiology and a prominent member of the human microbiota

Identifiants

pubmed: 32719505
doi: 10.1038/s41564-020-0763-4
pii: 10.1038/s41564-020-0763-4
pmc: PMC7581551
mid: NIHMS1607936
doi:

Substances chimiques

Antioxidants 0
Escherichia coli Proteins 0
Pteridines 0
Interleukin-10 130068-27-8
Sulfamethoxazole JE42381TNV

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1319-1329

Subventions

Organisme : NCI NIH HHS
ID : DP2 CA186575
Pays : United States
Organisme : NIGMS NIH HHS
ID : R00 GM097096
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : Howard Hughes Medical Institute
Pays : United States

Commentaires et corrections

Type : CommentIn

Références

Blount, Z. D. The unexhausted potential of E. coli. eLife 4, e05826 (2015).
pmcid: 4373459
Kaper, J. B., Nataro, J. P. & Mobley, H. L. Pathogenic Escherichia coli. Nat. Rev. Microbiol. 2, 123–140 (2004).
pubmed: 15040260
Tenaillon, O., Skurnik, D., Picard, B. & Denamur, E. The population genetics of commensal Escherichia coli. Nat. Rev. Microbiol. 8, 207–217 (2010).
pubmed: 20157339
Wassenaar, T. M. Insights from 100 years of research with probiotic E. coli. Eur. J. Microbiol. Immunol. 6, 147–161 (2016).
Mirsepasi-Lauridsen, H. C., Vallance, B. A., Krogfelt, K. A. & Petersen, A. M. Escherichia coli pathobionts associated with inflammatory bowel disease. Clin. Microbiol. Rev. 32, e00060-18 (2019).
pubmed: 30700431 pmcid: 6431131
Smilack, J. D. Trimethoprim-sulfamethoxazole. Mayo Clin. Proc. 74, 730–734 (1999).
pubmed: 10405706
Stallmach, A. et al. Medical and surgical therapy of inflammatory bowel disease in the elderly—prospects and complications. J. Crohns Colitis 5, 177–188 (2011).
pubmed: 21575879
Haußmann, C. et al. Biosynthesis of pteridines in Escherichia coli. Structural and mechanistic similarity of dihydroneopterin-triphosphate epimerase and dihydroneopterin aldolase. J. Biol. Chem. 273, 17418–17424 (1998).
pubmed: 9651328
Giladi, M. et al. FolM, a new chromosomally encoded dihydrofolate reductase in Escherichia coli. J. Bacteriol. 185, 7015–7018 (2003).
pubmed: 14617668 pmcid: 262705
Pribat, A. et al. FolX and FolM are essential for tetrahydromonapterin synthesis in Escherichia coli and Pseudomonas aeruginosa. J. Bacteriol. 192, 475–482 (2010).
pubmed: 19897652
Gelfand, D. H. & Steinberg, R. A. Escherichia coli mutants deficient in the aspartate and aromatic amino acid aminotransferases. J. Bacteriol. 130, 429–440 (1977).
pubmed: 15983 pmcid: 235221
Lobritz, M. A. et al. Antibiotic efficacy is linked to bacterial cellular respiration. Proc. Natl Acad. Sci. USA 112, 8173–8180 (2015).
pubmed: 26100898
Belenky, P. et al. Bactericidal antibiotics induce toxic metabolic perturbations that lead to cellular damage. Cell. Rep. 13, 968–980 (2015).
pubmed: 26565910 pmcid: 4648786
Mitosch, K., Rieckh, G. & Bollenbach, T. Noisy response to antibiotic stress predicts subsequent single-cell survival in an acidic environment. Cell. Syst. 4, 393–403 (2017).
pubmed: 28342718
Zampieri, M., Zimmermann, M., Claassen, M. & Sauer, U. Nontargeted metabolomics reveals the multilevel response to antibiotic perturbations. Cell. Rep. 19, 1214–1228 (2017).
pubmed: 28494870
Zampieri, M. et al. Metabolic constraints on the evolution of antibiotic resistance. Mol. Syst. Biol. 13, 917 (2017).
pubmed: 28265005 pmcid: 5371735
Zampieri, M. et al. High-throughput metabolomic analysis predicts mode of action of uncharacterized antimicrobial compounds. Sci. Transl. Med. 10, eaal3973 (2018).
pubmed: 29467300 pmcid: 6544516
Zampieri, M. et al. Regulatory mechanisms underlying coordination of amino acid and glucose catabolism in Escherichia coli. Nat. Commun. 10, 3354 (2019).
pubmed: 31350417 pmcid: 6659692
Anuforom, O., Wallace, G. R. & Piddock, L. V. The immune response and antibacterial therapy. Med. Microbiol. Immunol. 204, 151–159 (2015).
pubmed: 25189424
Rubin, B. K. & Tamaoki, J. Antibiotics as Anti-inflammatory and Immunomodulatory Agents (Springer Science & Business Media, 2005).
Cho, I. et al. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature 488, 621–626 (2012).
pubmed: 22914093 pmcid: 3553221
Schneditz, G. et al. Enterotoxicity of a nonribosomal peptide causes antibiotic-associated colitis. Proc. Natl Acad. Sci. USA 111, 13181–13186 (2014).
pubmed: 25157164
Lopez, C. A., Kingsbury, D. D., Velazquez, E. M. & Bäumler, A. J. Collateral damage: microbiota-derived metabolites and immune function in the antibiotic era. Cell Host Microbe 16, 156–163 (2014).
pubmed: 25121745 pmcid: 4151313
Becattini, S., Taur, Y. & Pamer, E. G. Antibiotic-induced changes in the intestinal microbiota and disease. Trends Mol. Med. 22, 458–478 (2016).
pubmed: 27178527 pmcid: 4885777
Dornisch, E. et al. Biosynthesis of the enterotoxic pyrrolobenzodiazepine natural product tilivalline. Angew. Chem. Int. Ed. 56, 14753–14757 (2017).
Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91–97 (2018).
Yang, J. H. et al. Antibiotic-induced changes to the host metabolic environment inhibit drug efficacy and alter immune function. Cell Host Microbe 22, 757–765 (2017).
pubmed: 29199098 pmcid: 5730482
Gopinath, S. et al. Topical application of aminoglycoside antibiotics enhances host resistance to viral infections in a microbiota-independent manner. Nat. Microbiol. 3, 611–621 (2018).
pubmed: 29632368 pmcid: 5918160
Park, H. B. et al. Bacterial autoimmune drug metabolism transforms an immunomodulator into structurally and functionally divergent antibiotics. Angew. Chem. Int. Ed. 59, 2–12 (2020).
Oh, J., Patel, J., Park, H. B. & Crawford, J. M. β-Lactam biotransformations activate innate immunity. J. Org. Chem. 83, 7173–7179 (2018).
pubmed: 29616809
Wormser, G. P., Keusch, G. T. & Heel, R. C. Co-trimoxazole (trimethoprim-sulfamethoxazole): an updated review of its antibacterial activity and clinical efficacy. Drugs 24, 459–518 (1982).
pubmed: 6759092
Baker, D. J. et al. The binding of trimethoprim to bacterial dihydrofolate reductase. FEBS Lett. 126, 49–52 (1981).
pubmed: 7016582
Achari, A. et al. Crystal structure of the anti-bacterial sulfonamide drug target dihydropteroate synthase. Nat. Struct. Biol. 4, 490–497 (1997).
pubmed: 9187658
Okada, B. K. & Seyedsayamdost, M. R. Antibiotic dialogues: induction of silent biosynthetic gene clusters by exogenous small molecules. FEMS Microbiol. Rev. 41, 19–33 (2017).
pubmed: 27576366
Kim, C. S. et al. Characterization of autoinducer-3 atructure and biosynthesis in E. coli. ACS Cent. Sci. 6, 197–206 (2020).
pubmed: 32123737 pmcid: 7047286
Nougayrède, J. P. et al. Escherichia coli induces DNA double-strand breaks in eukaryotic cells. Science 313, 848–851 (2006).
pubmed: 16902142
Xue, M. et al. Structure elucidation of colibactin and its DNA cross-links. Science 365, eaax2685 (2019).
Arthur, J. C. et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338, 120–123 (2012).
pubmed: 22903521 pmcid: 3645302
Arthur, J. C. et al. Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer. Nat. Commun. 5, 4724 (2014).
pubmed: 25182170 pmcid: 4155410
Cougnoux, A. et al. Small-molecule inhibitors prevent the genotoxic and protumoural effects induced by colibactin-producing bacteria. Gut 65, 278–285 (2016).
pubmed: 25588406
Tomkovich, S. et al. Locoregional effects of microbiota in a preclinical model of colon carcinogenesis. Cancer Res. 77, 2620–2632 (2017).
pubmed: 28416491 pmcid: 5468752
Dejea, C. M. et al. Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359, 592–597 (2018).
pubmed: 29420293 pmcid: 5881113
Wiegand, I., Hilpert, K. & Hancock, R. E. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat. Protoc. 3, 163–175 (2008).
pubmed: 18274517
Thomas, A. H. et al. Fluorescence of pterin, 6-formylpterin, 6-carboxypterin and folic acid in aqueous solution: pH effects. Photochem. Photobiol. Sci. 1, 421–426 (2002).
pubmed: 12856711
Kim, Y., Kang, Y. & Baek, D. Oxidative synthesis of benzoylpteridines from benzylpteridines by potassium penmanganate. Bull. Korean Chem. Soc. 22, 141–144 (2001).
Bermingham, A. & Derrick, J. P. The folic acid biosynthesis pathway in bacteria: evaluation of potential for antibacterial drug discovery. Bioessays 24, 637–648 (2002).
pubmed: 12111724
de Crécy-Lagard, V. et al. Comparative genomics of bacterial and plant folate synthesis and salvage: predictions and validations. BMC Genomics 8, 245 (2007).
pubmed: 17645794 pmcid: 1971073
Feirer, N. et al. A pterin-dependent signaling pathway regulates a dual-function diguanylate cyclase-phosphodiesterase controlling surface attachment in Agrobacterium tumefaciens. mBio 6, e00156-15 (2015).
pubmed: 26126849 pmcid: 4488946
Ahn, C., Byun, J. & Yim, J. Purification, cloning, and functional expression of dihydroneopterin triphosphate 2′-epimerase from Escherichia coli. J. Biol. Chem. 272, 15323–15328 (1997).
pubmed: 9182560
Shan, Y. et al. Genetic basis of persister tolerance to aminoglycosides in Escherichia coli. mBio 6, e00078-15 (2015).
pubmed: 25852159 pmcid: 4453570
Mathieu, A. et al. Discovery and function of a general core hormetic stress response in E. coli induced by sublethal concentrations of antibiotics. Cell. Rep. 17, 46–57 (2016).
pubmed: 27681420
Kim, C. S. et al. Cellular stress upregulates indole signaling metabolites in Escherichia coli. Cell Chem. Biol. 27, 698–707 (2020).
pubmed: 32243812
Perez, C. E., Park, H. B. & Crawford, J. M. Functional characterization of a condensation domain that links nonribosomal peptide and pteridine biosynthetic machineries in Photorhabdus luminescens. Biochemistry 57, 354–361 (2018).
pubmed: 29111689
Brown, G. M. The biosynthesis of pteridines. Adv. Enzymol. Relat. Areas Mol. Biol 35, 35–77 (1971).
Nichol, C. A. et al. Biosynthesis of tetrahydrobiopterin by de novo and salvage pathways in adrenal medulla extracts, mammalian cell cultures, and rat brain in vivo. Proc. Natl Acad. Sci. USA 80, 1546–1550 (1983).
pubmed: 6572916
Groehn, V. et al. Pteridine-based photoaffinity probes for nitric oxide synthase and aromatic amino acid hydroxylases. Helv. Chim. Acta 83, 2738–2750 (2000).
Crabtree, M. J. et al. Critical role for tetrahydrobiopterin recycling by dihydrofolate reductase in regulation of endothelial nitric-oxide synthase coupling: relative importance of the de novo biopterin synthesis versus salvage pathways. J. Biol. Chem. 284, 28128–28136 (2009).
pubmed: 19666465 pmcid: 2788863
Kirsch, M. et al. The autoxidation of tetrahydrobiopterin revisited. Proof of superoxide formation from reaction of tetrahydrobiopterin with molecular oxygen. J. Biol. Chem. 278, 24481–24490 (2003).
pubmed: 12714605
Oettl, K. & Reibnegger, G. Pteridines as inhibitors of xanthine oxidase: structural requirements. Biochim. Biophys. Acta 1430, 387–395 (1999).
pubmed: 10082966
Vásquez-Vivar, J. Tetrahydrobiopterin, superoxide, and vascular dysfunction. Free Radic. Biol. Med. 47, 1108–1119 (2009).
pubmed: 19628033 pmcid: 2852262
Kojima, S., Icho, T., Mori, H. & Arai, T. Enhancing potency of neopterin toward B-16 melanoma cell damage induced by UV-A irradiation and its possible application for skin tumor treatment. Anticancer Res. 15, 1975–1980 (1995).
pubmed: 8572587
Becker, C., Fantini, M. C. & Neurath, M. F. High resolution colonoscopy in live mice. Nat. Protoc. 1, 2900–2904 (2006).
pubmed: 17406549
Dorrestein, P. C., Mazmanian, S. K. & Knight, R. Finding the missing links among metabolites, microbes, and the host. Immunity 40, 824–832 (2014).
pubmed: 24950202 pmcid: 4503329
Kruis, W. et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53, 1617–1623 (2004).
pubmed: 15479682 pmcid: 1774300
Palmela, C. et al. Adherent-invasive Escherichia coli in inflammatory bowel disease. Gut 67, 574–587 (2018).
pubmed: 29141957
Rembacken, B. J. et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354, 635–639 (1999).
pubmed: 10466665
Smith, S. G. & Goodman, J. M. Assigning the stereochemistry of pairs of diastereoisomers using GIAO NMR shift calculation. J. Org. Chem. 74, 4597–4607 (2009).
pubmed: 19459674
Kamanaka, M. et al. Expression of interleukin-10 in intestinal lymphocytes detected by an interleukin-10 reporter knockin tiger mouse. Immunity 25, 941–952 (2006).
pubmed: 17137799

Auteurs

Hyun Bong Park (HB)

Department of Chemistry, Yale University, New Haven, CT, USA.
Chemical Biology Institute, Yale University, West Haven, CT, USA.

Zheng Wei (Z)

Chemical Biology Institute, Yale University, West Haven, CT, USA.
Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.

Joonseok Oh (J)

Department of Chemistry, Yale University, New Haven, CT, USA.
Chemical Biology Institute, Yale University, West Haven, CT, USA.

Hao Xu (H)

Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.

Chung Sub Kim (CS)

Department of Chemistry, Yale University, New Haven, CT, USA.
Chemical Biology Institute, Yale University, West Haven, CT, USA.
School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.

Rurun Wang (R)

Exploratory Science Center, Merck & Co., Inc., Cambridge, MA, USA.

Thomas P Wyche (TP)

Exploratory Science Center, Merck & Co., Inc., Cambridge, MA, USA.

Grazia Piizzi (G)

Exploratory Science Center, Merck & Co., Inc., Cambridge, MA, USA.

Richard A Flavell (RA)

Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA. richard.flavell@yale.edu.
Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, CT, USA. richard.flavell@yale.edu.

Jason M Crawford (JM)

Department of Chemistry, Yale University, New Haven, CT, USA. jason.crawford@yale.edu.
Chemical Biology Institute, Yale University, West Haven, CT, USA. jason.crawford@yale.edu.
Department of Microbial Pathogenesis, Yale University School of Medicine, New Haven, CT, USA. jason.crawford@yale.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH